

Deep Pharma Intelligence Releases Industry Report - Landscape of AI Companies in Real World Studies

Deep Pharma Intelligence, the Yuan and Evomics Medical released a joint report "Landscape of AI Companies in Real World Studies".

LONDON, UK, October 27, 2021

/EINPresswire.com/ -- [Deep Pharma Intelligence](#), a leading UK-based

strategy consulting agency, [the YUAN](#), a rapidly growing tech community

focused on artificial intelligence (AI) in healthcare, and [Evomics Medical](#), a

global healthcare technology company,

today release a joint analytical report "Landscape of AI Technology Companies in Real World Studies", which is a unique product combining insights about companies both in "Western world" and Asian region, China in particular.



Deep Pharma Intelligence - The Yuan

“

We are happy to have The YUAN and Evomics Medical as co-creators of this joint report, providing unique insights about the market of medical AI in Asia region, and in China in particular.”

Dr. Andrii Buvailo, Co-founder, Director Deep Pharma Intelligence


The aim of this report is to provide insights about the emerging and rapidly developing area of applying Artificial Intelligence (AI) technologies to conducting real world studies (RWS), and integrating such studies and their outputs into the pharmaceutical and healthcare research workflows, such as drug development and evidence-based medicine. The report is a unique study that is revealing trends in the area of medical AI not only in the “Western world”, but also in the largely underestimated by western media Asian part of the globe, in particular -- in China. The report gives a bird’s eye view and understanding of policies, business ecosystem, scope of available products

and services in the area of AI in RWS -- both in the West, and in the East.

This 110 page report marks the inaugural work by Deep Pharma Intelligence, in close

collaboration with its China partners The YUAN and Evomics Medical, and lays foundation for the upcoming series of market studies in the area of pharmaceutical AI in China and Asia.

The industry has its own leaders cutting through technologies that can increase role and influence on the overall success of drug discovery and pharmaceutical business. Alongside investment and business trends, the report also provides technical insights into some of the latest achievements in the applications of various flavors of AI technologies.



The report highlights key players, industry developments, case studies, and trends in the following categories: Drug Development, Big Data, and Biomarkers. Each category deeply and reliably exposes key insights in today's field development. The growing amount of wearable devices and innovation in IoT facilitate the expansion of advanced technology providers into the pharmaceutical industry creating new evidence-based data analytics.

Access this new report "Landscape of AI Technology Companies in Real World Studies Industry" at: <https://www.deep-pharma.tech/rws-landscape-report>

About Deep Pharma Intelligence

Deep Pharma Intelligence is a joint venture of Deep Knowledge Analytics Pharma Division and BPT Analytics (BiopharmaTrend) producing powerful data mining and visualization systems, interactive analytics dashboards and industry reports offering deep technical insights, business intelligence, competitive analysis, industry benchmarking and strategic guidance in high growth and large opportunity areas of the pharma sector, including AI in drug discovery, emerging therapeutic targets and drug modalities, new therapies and technologies, promising startups, and more.

About The Yuan

The Yuan is a new tech community platform focused on AI in healthcare, ML and related disciplines. Their aim is to provide an open forum for global innovators, entrepreneurs and others in the AI world to exchange insights into this transformational technology. The company is seeking talented AI professionals and social commentators to share their expertise and wisdom to inform our readership of investors, scientists, researchers, engineers, graduate students, policymakers, healthcare providers and patients, and the public at large, of developments in this novel arena that is poised to become central to every of field of human endeavor.

About Evomics Medical

Evomics Medical is a global healthcare technology company working to provide an

unprecedented holistic approach to precision medicine. With scientifically proven AI solutions, the company integrates traditional and deep learning for tumor characterization using medical imaging and non-imaging data to increase the quality of doctor's decision-making. Evomics' team is made up of renowned entrepreneurs, imaging physicists, physicians, and computer scientists from Medical University of Vienna, AKH, ShangPharma, Siemens, Alibaba, Humana, AiFi and more.

About Deep Knowledge Group

Deep Knowledge Group is an international consortium of commercial and non-profit organizations focused on the synergetic convergence of DeepTech and Frontier Technologies (AI, Longevity, MedTech, FinTech, GovTech), applying progressive data-driven Invest-Tech solutions with a long-term strategic focus on AI in Healthcare, Longevity and Precision Health, and aiming to achieve positive impact through the support of progressive technologies for the benefit of humanity via scientific research, investment, entrepreneurship, analytics and philanthropy.

For press and media inquiries, please contact: info@deep-pharma.tech

Helen Uvarenko

Deep Pharma Intelligence

[email us here](#)

Visit us on social media:

[Twitter](#)

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/554871999>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2021 IPD Group, Inc. All Right Reserved.